15d-PGJ2 modulates acute immune responses to Trypanosoma cruzi infection

Memorias do Instituto Oswaldo Cruz

Volumn 105, Issue 2, 2010, Pages 137-143

  Rodrigues, Wellington F ^a   Miguel, Camila B ^b   Chica, Javier E Lazo ^b   Napimoga, Marcelo H ^a  

^a UNIVERSITY OF UBERABA   (Brazil)

^b Univ Hosp Triangulo Mineiro M S   (Brazil)

Author keywords

15d PGJ2; Chagas disease; PPAR gamma; Trypanosoma cruzi

Indexed keywords

ANIMALIA; MUS; TRYPANOSOMA CRUZI;

EID: 77951922468     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762010000200005     Document Type: Article

References (33)

1. Abel LC, Rizzo LV, Lanni B, Albuquerque F, Bacal F, Carrara D, Bocchi EA, Teixeira HC, Mady C, Kalil J, Cunha-Neto E 2001. Chronic Chagas' disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruzi infection. J Autoimmun 17: 99-107.
2. Bassaganya-Riera J, Guri A, King J, Hontecillas R 2005. Peroxisome proliferator-activated receptors: the nutritionally controlled molecular networks that integrate inflammation, immunity and metabolism. Curr Nutr Food Sci 1: 179-187.
3. Boggild AK, Krudsood S, Patel SN, Serghides L, Tangpukdee N, Katz K, Wilairatana P, Liles WC, Looareesuwan S, Kain KC 2009. Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 49: 841-849.
4. Cardillo F, Voltarelli JC, Reed SG, Silva JS 1996. Regulation of Trypanosoma cruzi infection in mice by gamma interferon and interleukin 10: role of NK cells. Infect Immun 64: 128-134.
5. Chagas CRJ 1909. Nova tripanosomíase humana. Estudos sobre a morphologia e o ciclo evolutivo do Schizotrypanum cruzi n. gen. n. esp., agente da nova entidade mórbida do homem. Mem Inst Oswaldo Cruz 1: 159-218.
6. Chinetti G, Fruchart JC, Staels B 2000. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 49: 497-505.
7. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B 1998. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573-25580.
8. Costa GC, da Costa Rocha MO, Moreira PR, Menezes CA, Silva MR, Gollob KJ, Dutra WO 2009. Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy. J Infect Dis 199: 451-454.
9. Coura JR, De Castro SL 2002. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
10. Dias JC 2007. Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation and perspectives. Mem Inst Oswaldo Cruz 102: 11-18.
11. Di Paola R, Cuzzocrea S 2007. Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury. Naunyn Schmiedebergs Arch Pharmacol 375: 157-17.
12. Dutra WO, Menezes CA, Villani FN, da Costa GC, da Silveira AB, Reis D, Gollob KJ 2009. Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz 104: 208-218.
13. Freire-de-Lima CG, Nascimento DO, Soares MBP, De Mello FG, Bozza PT, Castro-Faria-Neto HC, Dosreis GA, Lopes MF 2000. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 403: 199-203.
14. Garcia S, Ramos CO, Senra JF, Senra JFV, Vilas-Boas F, Rodrigues MM, Campos-de-Carvalho AC, Ribeiro-dos-Santos R, Soares MBP 2005. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob Agents Chemother 49: 1521-1528.
15. Guri AJ, Hontecillas R, Bassaganya-Riera J 2006. Peroxisome proliferator-activated receptors: bridging metabolic syndrome with molecular nutrition. Clin Nutr 25: 871-885.
16. Gutierrez FR, Guedes PM, Gazzinelli RT, Silva JS 2009. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol 31: 673-685.
17. Hassumi MY, Silva-Filho VJ, Campos-Júnior JC, Vieira SM, Cunha FQ, Alves PM, Alves JB, Kawai T, Gonçalves RB, Napimoga MH 2009. PPAR-γ agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int Immunopharmacol 9: 1150-1158.
18. Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, Alferink J, Novak N, Beyer M, Mayer G, Langhans B, Klockgether T, Waisman A, Eberl G, Schultze J, Famulok M, Kolanus W, Glass C, Kurts C, Knolle PA 2009. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cellintrinsic fashion and suppresses CNS autoimmunity. J Exp Med 10: 2079-2089.
19. Kotner J, Tarleton R 2007. Endogenous CD25+ regulatory T cells have a limited role in the control of Trypanossoma cruzi infection in mice. Infect Immun 75: 861-869.
20. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA 1997. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal antiinflammatory drugs. J Biol Chem 272: 3406-3410.
21. Mandarim-de-Lacerda CA 2003. Stereological tools in biomedical research. An Acad Bras Cienc 75: 469-486.
22. Marino AP, Silva AA, Santos PV, Pinto LM, Gazinelli RT, Teixeira MM, Lannes-Vieira J 2005. CC-chemokine receptors: a potential therapeutic target for Trypanosoma cruzi-elicited myocarditis. Mem Inst Oswaldo Cruz 100: 93-96.
23. Medeiros GA, Silvério JC, Marino AP, Roffê E, Vieira V, Kroll-Palhares K, Carvalho CE, Silva AA, Teixeira MM, LannesVieira J 2009. Treatment of chronically Trypanosoma cruziinfected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect 11: 264-273.
24. Michelin MA, Silva JS, Cunha FQ 2005. Inducible cyclooxygenase released prostaglandin mediates immunosuppression in acute phase of experimental Trypanosoma cruzi infection. Exp Parasitol 111: 71-79.
25. Nagajyothi F, Desruisseaux MS, Weiss LM, Chua S, Albanese C, Machado FS, Esper L, Lisanti MP, Teixeira MM, Scherer PE, Tanowitz HB 2009. Chagas disease, adipose tissue and the metabolic syndrome. Mem Inst Oswaldo Cruz 104: 219-225.
26. Napimoga MH, Vieira SM, Secco-dal D, Freitas A, Souto FO, Mestriner FL, Filho-Alves JC, Grespan R, Kawai T, Ferreira SH, Cunha FQ 2008. Peroxisome proliferator-activated receptor-γ ligand, 15-deoxy-Δ12,14-prostaglandin J2, reduces neutrophil migration via a nitric oxide pathway. J Immunol 180: 609-617.
27. Park SJ, Lee KS, Kim SR, Min KH, Choe YH, Moon H, Chae HJ, Yoo WH, Lee YC 2009. Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. J Immunol 5: 3259-3267.
28. Ribeirao M, Pereira-Chioccola VL, Renia L, Augusto Fragata Filho A, Schenkman S, Rodrigues MM 2000. Chagasic patients develop a type 1 immune response to Trypanosoma cruzi transsialidase. Parasite Immunol 22: 49-53.
29. Serghides L, Patel SN, Ayi K, Lu Z, Gowda DC, Liles WC, Kain KC 2009. Rosiglitazone modulates innate immune responses to Plasmodium falciparum and improves outcome in experimental cerebral malaria. J Infect Dis 199: 1536-1545.
30. Tarleton RL, Zhang L 1999. Chagas disease etiology: autoimmunity or parasite persistence? Parasitol Today 15: 94-99.
31. Torrico F, Heremans H, Rivera MT, Van Marck E, Billiau A, Carlier Y 1991. Endogenous IFN-gamma is required for resistance to acute Trypanosoma cruzi infection in mice. J Immunol 146: 3626-3632.
32. Urbina JA, Do Campo R 2003. Specific chemotherapy of Chagas disease: controversies and advances. Trends in Parasitol 19: 495-500.
33. Wilkinson SR, Kelly JM 2009. Trypanocidal drugs: mechanisms, resistance and new targets. Expert Rev Mol Med 29: 11-31.